ATXI - Avenue Therapeutics Inc
IEX Last Trade
2.59
0.070 2.703%
Share volume: 6,688
Last Updated: Fri 30 Aug 2024 04:06:39 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$2.52
0.07
2.78%
Fundamental analysis
27%
Profitability
27%
Dept financing
11%
Liquidity
50%
Performance
25%
Performance
5 Days
-13.90%
1 Month
-8.96%
3 Months
-29.64%
6 Months
-77.66%
1 Year
-95.95%
2 Year
-99.10%
Key data
Stock price
$2.59
DAY RANGE
N/A - N/A
52 WEEK RANGE
$2.25 - $64.27
52 WEEK CHANGE
-$0.96
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO:
Region: US
Website: http://www.avenuetx.com/
Employees: 11
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: http://www.avenuetx.com/
Employees: 11
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
avenue therapeutics, inc. (nasdaq: atxi), a fortress biotech (nasdaq: fbio) company, is a specialty pharmaceutical company focused on the development and commercialization of intravenous (iv) tramadol for the management of moderate to moderately severe postoperative pain. iv tramadol may fill a gap in the acute pain market between iv acetaminophen/nsaids and iv conventional narcotics. avenue is currently evaluating iv tramadol in a pivotal phase 3 program for the management of postoperative pain.
Recent news